Merck Q1 Earnings & Sales Beat Estimates, '25 EPS Outlook Cut

Merck (MRK) reported first-quarter 2025 adjusted earnings per share (EPS) of $2.22, which beat the Zacks Consensus Estimate of $2.15. Earnings rose 7% year over year on a reported basis and 12% excluding foreign exchange (Fx). This upside was primarily driven by a one-time charge incurred by the company in the year-ago quarter for the acquisition of Harpoon Therapeutics, which was completed in March 2024.Revenues declined 2% year over year (up 1% excluding Fx) to $15.53 billion. Sales also beat the Zacks Co ...